Director Laurent Fischer of Lycia Therapeutics, Inc. filed a Form 4 on October 26, 2026, disclosing the acquisition of two stock option grants covering a combined 33,307 shares of common stock.

Key Highlights

  • First option grant: 13,307 stock options acquired on August 11, 2026, at an exercise price of $3.70, expiring August 10, 2036.
  • Second option grant: 20,000 stock options acquired on October 22, 2026, at an exercise price of $18.00, expiring October 21, 2036.
  • Price paid: Both grants were acquired at $0 (no cost to the reporting person at grant).
  • Vesting schedule (13,307 options): Options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026.
  • Vesting schedule (20,000 options): Options vest as to 100% of the award on October 22, 2027.
  • Reporting person role: Laurent Fischer is identified as a Director of Lycia Therapeutics, Inc. (NASDAQ:LYCA).

Details of Laurent Fischer's Option Grants at Lycia Therapeutics

According to the Form 4 filed on October 26, 2026, Director Laurent Fischer reported two separate acquisitions of stock options (rights to buy) in Lycia Therapeutics, Inc. The first grant, dated August 11, 2026, covers 13,307 shares of common stock at an exercise price of $3.70 per share, with an expiration date of August 10, 2036. The filing notes that "the transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a)."

The 13,307 options vest as to 1/48 of the total award monthly over four years, with the first tranche having vested on September 6, 2026, subject to Fischer's continued service to the issuer on each vesting date. The second grant, dated October 22, 2026, covers 20,000 shares of common stock at an exercise price of $18.00 per share, expiring October 21, 2036. These options will vest as to 100% of the award on October 22, 2027, also subject to continued service. Both grants were acquired at a price of $0 and are held directly by the reporting person.

Following both reported transactions, Fischer beneficially owns 13,307 derivative securities from the first grant and 20,000 from the second, each held in direct ownership form, according to the filing. The Form 4 was signed by Amy Bachrodt as Attorney-in-Fact on October 26, 2026.

What Was Disclosed

Director Laurent Fischer disclosed the acquisition of two stock option grants from Lycia Therapeutics, Inc., totaling 33,307 options to purchase common stock, with exercise prices of $3.70 and $18.00 respectively, and differing vesting schedules, all reported via Form 4 filed October 26, 2026.